STELLENBOSCH UNIVERSITY

Curevo's Amezosvatein Shows Sustained Immunogenicity and Improved Tolerability in Phase 2 Shingles Vaccine Trial

4 months ago

• Curevo's amezosvatein maintained non-inferior anti-gE antibody levels compared to Shingrix one year after the second dose in adults aged 50-69. • The Phase 2 trial (NCT05304351) demonstrated that amezosvatein had a statistically significant improvement in Grade 2 and 3 reactogenicity versus Shingrix. • No confirmed shingles cases were observed in the highest antigen dose arms of amezosvatein or the Shingrix arm during the post-hoc analysis. • Curevo plans to advance amezosvatein into global Phase 3 trials in 2025, targeting the multi-billion dollar shingles vaccine market.

First Clinical Trial of DM199 Launched to Combat Preeclampsia

5 months ago

• Stellenbosch University initiates a clinical trial for DM199, a novel drug targeting the root cause of preeclampsia, a severe pregnancy complication. • DM199, a synthetic form of tissue-kallikrein-1, aims to improve blood vessel health by addressing endothelial dysfunction, unlike current treatments focused on managing blood pressure. • The trial employs a phased approach, starting with low doses to ensure safety for both the mother and the unborn child, addressing a critical gap in maternal healthcare. • This study marks a significant advancement, offering a potential targeted treatment for preeclampsia, which affects 5% of pregnancies and results in numerous maternal and fetal deaths.

DiaMedica Receives SAHPRA Approval to Commence Phase II Preeclampsia Trial with DM199

7 months ago

• DiaMedica Therapeutics gains approval from SAHPRA to begin a Phase II clinical trial of DM199 for preeclampsia treatment. • The trial will be conducted at Tygerberg Hospital in Cape Town, South Africa, enrolling up to 90 women with preeclampsia. • The study aims to assess DM199's safety and ability to lower maternal blood pressure and improve placental blood flow. • Top-line results from Part 1a of the trial are expected in the first half of next year, offering proof of concept for DM199.